Mini Reviews
Vol. 21 No. 4 (2025)
How to manage a severe form of euglycemic diabetic ketoacidosis caused by SGLT2 inhibitors: a case report and literature review
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Received: 12 June 2025
Accepted: 4 September 2025
Accepted: 4 September 2025
299
Views
168
Downloads
Authors
The use of sodium-glucose cotransporter-2 inhibitors is becoming increasingly widespread not only for the treatment of diabetes mellitus, but also for heart failure and kidney disease. However, these medications can lead to very severe complications, sometimes even fatal, such as Euglycemic Ketoacidosis (EDKA). In this report, we present the case of a 79-year-old woman, affected by type 2 diabetes mellitus on insulin therapy and empagliflozin, who was admitted to our emergency department for a severe EDKA. Treatment with bicarbonates did not improve her condition worsening the hypokalaemia and complicating the administration of insulin. For this reason, we decided to administer octreotide subcutaneously with a rapid resolution of EDKA and an improvement in clinical conditions, demonstrating that octreotide can be an excellent therapeutic option for EDKA. Starting from our experience, we conducted a review of the relevant literature on this issue.
Downloads
Download data is not yet available.
Citations
1. Semirani-Nezhad D, Soleimani H, Taebi M, et al. Early initiation of SGLT2 inhibitors in acute myocardial infarction and cardiovascular outcomes, an updated systematic review and meta-analysis. BMC Cardiovasc Disord 2025;25:527. DOI: https://doi.org/10.1186/s12872-025-04992-2
2. Spiazzi BF, Piccoli GF, Wayerbacher LF, et al. SGLT2 inhibitors, cardiovascular outcomes, and mortality across the spectrum of kidney disease: A systematic review and meta-analysis. Diabetes Res Clin Pract 2024;218:111933. DOI: https://doi.org/10.1016/j.diabres.2024.111933
3. Morace C, Lorello G, Bellone F, et al. Ketoacidosis and SGLT2 inhibitors: a narrative review. Metabolites 2024;14:264. DOI: https://doi.org/10.3390/metabo14050264
4. Singh M, Kumar A. Risks associated with SGLT2 inhibitors: an overview. Curr Drug Saf 2018;13:84-91. DOI: https://doi.org/10.2174/1574886313666180226103408
5. Torre A, Bisogno N, Botta C, et al. Treatment of a severe form of euglycemic ketoacidosis in a patient treated with SGLT-2 inhibitors with the aid of somatostatin. G Ital Nefrol 2023;40:2023-vol4.
6. Marzbach P, Bauer W, Bodmer D, et al. Discovery and development of somatostatin agonist. Pharm Biotecnolol 1998;11:183-209. DOI: https://doi.org/10.1007/0-306-47384-4_9
7. Seewi O, Vierzig A, Roth B, Schönau E. Symptomatic cerebral oedema during treatment of diabetic ketoacidosis: effect of adjuvant octreotide infusion. Diabetol Metab Syndr 2010;2:56. DOI: https://doi.org/10.1186/1758-5996-2-56
8. Malherbe J, du Cheyron D, Valette X. Understanding the disease: euglycemic ketoacidosis with SGLT2 inhibitors. Intensive Care Med 2025;51:779-82. DOI: https://doi.org/10.1007/s00134-025-07806-3
9. Liu Y, Yang S, Jiang A, et al. Risk of diabetic ketoacidosis caused by sodium glucose cotransporter-2 inhibitors in patients with type 1 diabetes: a systematic review and network meta-analysis of randomized controlled trials. Meta-Analysis Front Endocrinol (Lausanne) 2025:15:1453067. DOI: https://doi.org/10.3389/fendo.2024.1453067
10. Menghoum N, Oriot P, Hermans MP, Mariage JL. Diabetic euglycemic ketosis or ketoacidosis in individuals with type 2 diabetes treated by SGLT2 inhibitors: A series of Belgian clinical cases. Rev Med Interne 2020; 41:226-231. DOI: https://doi.org/10.1016/j.revmed.2019.12.006
11. Yii ESS, Azli AW, Sitaram PN. Sodium-glucose cotransporter 2 inhibitor-induced euglycemic diabetic ketoacidosis in a patient with coronavirus disease 2019: a case report. J Med Case Rep 2022;16:17. DOI: https://doi.org/10.1186/s13256-021-03232-3
12. Karakaya Z, Topal FE, Topal F, et al. Euglisemic diabetic ketoacidotic coma caused by dapagliflozin. Am J Emerg Med 2018;36:2136.e1-2136.e2. DOI: https://doi.org/10.1016/j.ajem.2018.08.054
13. Branco A, Fatima R, Liblik K, et al. Euglycemic diabetic ketoacidosis associated with sodium-glucose cotransporter-2 inhibitors after cardiac surgery: a review of current literature. J Cardiothorac Vasc Anesth 2022;36:3877-86.
14. Harano Y, Ohgaku S. Efficacy of combined insulin and somatostatin infusion for the treatment of experimental diabetic ketoacidosis. Horm Metab Res 1979;11:338-42 DOI: https://doi.org/10.1055/s-0028-1092734
15. Munro JF, Campbell IW, McCuish AC, Duncan LJ. Euglycaemic diabetic ketoacidosis. Br Med J 1973;2:578-80. DOI: https://doi.org/10.1136/bmj.2.5866.578
16. Long B, Lentz S, Koyfman A, Gottlieb M. Euglycemic diabetic ketoacidosis: Etiologies, evaluation, and management. Am J Emerg Med 2021;44:157-160.
17. Hsia DS, Grove O, Cefalu WT. An update on SGLT2 inhibitors for the treatment of diabetes mellitus. Curr Opin Endocrinol Diabetes Obes 2018;24:73–9. DOI: https://doi.org/10.1097/MED.0000000000000311
18. Sampani E, Sarafidis P, Dimitriadis C, et al. Severe euglycemic diabetic ketoacidosis of multifactorial etiology in a type 2 diabetic patient treated with empagliflozin: case report and literature review. BMC Nephrol 2020;21:276. DOI: https://doi.org/10.1186/s12882-020-01930-6
19. Chow E, Clement S, Garg R. Euglycemic diabetic ketoacidosis in the era of SGLT-2 inhibitors. BMJ Open Diabetes Res Care 2023;11:e003666. DOI: https://doi.org/10.1136/bmjdrc-2023-003666
20. Huang J, Yeung AM, Bergenstal RM, et al. Update on measuring ketones. J Diabetes Sci Technol 2024;18:714-26. DOI: https://doi.org/10.1177/19322968231152236
21. Shi Q, Nong K, Vandvik PO, et al. Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ 2023;381:e074068. DOI: https://doi.org/10.1136/bmj-2022-074068
22. Musso G, Saba F, Cassader M, Gambino R, 2020 Diabetic ketoacidosis with SGLT2 inhibitors. BMJ 2020:371:m4147. DOI: https://doi.org/10.1136/bmj.m4147
23. Bonner C, Kerr-Conte J, Gmyr V, et al. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med 2015;21:512–7. DOI: https://doi.org/10.1038/nm.3828
24. Danne T, Garg S, Peters AL, et al. International consensus on risk management of diabetic ketoacidosis in patients with type 1 diabetes treated with sodium-glucose cotransporter (SGLT) inhibitors. Diabetes Care 2019;42:1147–54. DOI: https://doi.org/10.2337/dc18-2316
25. Garcia B, Ostermann M, Legrand M, 2024 How to manage sodium-glucose cotransporter-2 inhibitors in the critically ill patient? Intensive Care Med 2025;51:143-5. DOI: https://doi.org/10.1007/s00134-024-07704-0
26. Iqbal I, Hamid M, Khan MAA, et al. Dapagliflozin-induced late-onset euglycemic diabetic ketoacidosis. Cureus 2019;11:e6089. DOI: https://doi.org/10.7759/cureus.6089
27. Dhatariya KK; Joint British Diabetes Societies for Inpatient Care. The management of diabetic ketoacidosis in adults-An updated guideline from the Joint British Diabetes Society for Inpatient Care. Diabet Med 2022;39:e14788. DOI: https://doi.org/10.1111/dme.14788
28. Branco A, Fatima R, Liblik K, et al. Euglycemic diabetic ketoacidosis associated with sodium-glucose cotransporter-2 inhibitors after cardiac surgery: a review of current literature. J Cardiothorac Vasc Anesth 2022;36:3877-86. DOI: https://doi.org/10.1053/j.jvca.2022.06.008
29. Long B, Lentz S, Koyfman A, Gottlieb M. Euglycemic diabetic ketoacidosis: Etiologies, evaluation, and management. Am J Emerg Med 2021;44:157-60. DOI: https://doi.org/10.1016/j.ajem.2021.02.015
How to Cite
How to manage a severe form of euglycemic diabetic ketoacidosis caused by SGLT2 inhibitors: a case report and literature review. (2025). Emergency Care Journal, 21(4). https://doi.org/10.4081/ecj.2025.14072
Copyright (c) 2025 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
